24Dec 2022
Long‐term efficacy and safety of idebenone in patients with Leber's hereditary optic neuropathy (LHON) in the chronic phase: Results from the prospective, natural history‐controlled LEROS study

Long‐term efficacy and safety of idebenone in patients with Leber's hereditary optic neuropathy (LHON) in the chronic phase: Results from the prospective, natural history‐controlled LEROS study

The study reports primary results from LEROS, a Phase 4, externally controlled interventional study in patients with chronic LHON (1 to ≤5 years since onset) treated with idebenone for up to 24 months. As was observed in the subacute/dynamic phase, the frequency of a CRB from baseline at 12 months was significantly higher in treated, chronic eyes than in matched NH eyes. LEROS provides evidence of a significant therapeutic benefit of idebenone treatment in patients with LHON in the chronic stage up to 5 years from onset.

  • #ophthalmology

Like

Save

Share